Recruiting 146 medically fit patients in this trial might be difficult given the generally low prevalence of NPM1-mutated, FLT3-wildtype AML and the emerging relevance of NPM1 directed therapies, i.e. menin inhibitors [21, 22]. This evidence concerns the gene FLT3 and acute myeloid leukemia.